Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
597.26
-7.36 (-1.22%)
May 22, 2025, 12:26 PM - Market open

Regeneron Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 23 professional analysts, the 12-month price target for Regeneron Pharmaceuticals stock ranges from a low of $547 to a high of $1,200. The average analyst price target of $905.22 forecasts a 51.56% increase in the stock price over the next year.

Price Target: $905.22 (+51.56%)
Analyst Consensus: Buy
Target Low Average Median High
Price $547 $905.22 $940 $1,200
Change -8.42% +51.56% +57.39% +100.92%

Analyst Ratings

The average analyst rating for Regeneron Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating Dec '24Jan '25Feb '25Mar '25Apr '25May '25
Strong Buy 777767
Buy 121213121212
Hold 455543
Sell 111111
Strong Sell 000000
Total 242526252323

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
Citigroup
Citigroup
Strong Buy
Upgrades
$600$700
Strong Buy Upgrades $600$700 +17.20% May 14, 2025
Guggenheim
Guggenheim
Strong Buy
Maintains
$940$810
Strong Buy Maintains $940$810 +35.62% May 1, 2025
Truist Securities
Truist Securities
Strong Buy
Maintains
$975$940
Strong Buy Maintains $975$940 +57.39% Apr 30, 2025
Goldman Sachs
Goldman Sachs
Strong Buy
Maintains
$917$804
Strong Buy Maintains $917$804 +34.61% Apr 30, 2025
RBC Capital
RBC Capital
Buy
Maintains
$1,051$943
Buy Maintains $1,051$943 +57.89% Apr 30, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
13.66B
from 14.20B
Decreased by -3.81%
Revenue Next Year
14.61B
from 13.66B
Increased by 6.97%
EPS This Year
36.37
from 38.34
Decreased by -5.13%
EPS Next Year
40.73
from 36.37
Increased by 11.96%
Fiscal Year FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 FY 2027
Period Ending Dec 31, 2020 Dec 31, 2021 Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025 Dec 31, 2026 Dec 31, 2027
Revenue
8.50B16.07B12.17B13.12B14.20B13.66B14.61B16.24B
Revenue Growth
29.58%89.14%-24.26%7.76%8.27%-3.81%6.97%11.13%
EPS
30.5271.9738.2234.7738.3436.3740.7350.22
EPS Growth
65.33%135.81%-46.90%-9.03%10.27%-5.13%11.96%23.31%
Forward PE
-----16.4214.6611.89
No. Analysts
-----302822
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 20252026202720282029
High 14.9B 16.5B 18.0B
Avg 13.7B 14.6B 16.2B
Low 12.3B 12.5B 14.2B

Revenue Growth

Revenue Growth 20252026202720282029
High
5.0%
20.4%
23.3%
Avg
-3.8%
7.0%
11.1%
Low
-13.1%
-8.7%
-2.5%

EPS Forecast

EPS 20252026202720282029
High 44.47 56.34 67.01
Avg 36.37 40.73 50.22
Low 28.47 30.93 37.92

EPS Growth

EPS Growth 20252026202720282029
High
16.0%
54.9%
64.5%
Avg
-5.1%
12.0%
23.3%
Low
-25.7%
-15.0%
-6.9%
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.